Research ArticleSpecial Contribution
MIRD Pamphlet No. 16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates
Jeffry A. Siegel, Stephen R. Thomas, James B. Stubbs, Michael G. Stabin, Marguerite T. Hays, Kenneth F. Koral, James S. Robertson, Roger W. Howell, Barry W. Wessels, Darrell R. Fisher, David A. Weber and A. Bertrand Brill
Journal of Nuclear Medicine February 1999, 40 (2) 37S-61S;
Jeffry A. Siegel
Stephen R. Thomas
James B. Stubbs
Michael G. Stabin
Marguerite T. Hays
Kenneth F. Koral
James S. Robertson
Roger W. Howell
Barry W. Wessels
Darrell R. Fisher
David A. Weber


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
MIRD Pamphlet No. 16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates
Jeffry A. Siegel, Stephen R. Thomas, James B. Stubbs, Michael G. Stabin, Marguerite T. Hays, Kenneth F. Koral, James S. Robertson, Roger W. Howell, Barry W. Wessels, Darrell R. Fisher, David A. Weber, A. Bertrand Brill
Journal of Nuclear Medicine Feb 1999, 40 (2) 37S-61S;
MIRD Pamphlet No. 16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates
Jeffry A. Siegel, Stephen R. Thomas, James B. Stubbs, Michael G. Stabin, Marguerite T. Hays, Kenneth F. Koral, James S. Robertson, Roger W. Howell, Barry W. Wessels, Darrell R. Fisher, David A. Weber, A. Bertrand Brill
Journal of Nuclear Medicine Feb 1999, 40 (2) 37S-61S;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
- Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects
- Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy
- Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
- MIRD Pamphlet No. 28, Part 1: MIRDcalc--A Software Tool for Medical Internal Radiation Dosimetry
- Dosimetry in Radiopharmaceutical Therapy
- 68Ga-Citrate PET of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
- RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 2--Data Analysis and Dosimetry
- RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 1--Collection of Data for Radiopharmaceutical Dosimetry
- An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge
- Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
- Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
- A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE
- Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
- Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE
- Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- The Relevance of Dosimetry in Precision Medicine
- 18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients
- Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
- Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
- Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
- Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy
- New Approaches for Modeling Radiopharmaceutical Pharmacokinetics Using Continuous Distributions of Rates
- A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of 99mTc-Sestamibi in Pediatric Subjects
- Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel 18F-Labeled Tracer for Imaging Myocardial Innervation
- (S)-4-(3-18F-Fluoropropyl)-L-Glutamic Acid: An 18F-Labeled Tumor-Specific Probe for PET/CT Imaging--Dosimetry
- Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
- MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
- Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine Tumors
- First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
- Phase I, First-in-Human Study of BMS747158, a Novel 18F-Labeled Tracer for Myocardial Perfusion PET: Dosimetry, Biodistribution, Safety, and Imaging Characteristics After a Single Injection at Rest
- Dosimetry and thyroid cancer: the individual dosage of radioiodine
- Influence of Vitamin C on Salivary Absorbed Dose of 131I in Thyroid Cancer Patients: A Prospective, Randomized, Single-Blind, Controlled Trial
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
- Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma
- Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
- MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
- Radiopharmaceuticals for Nuclear Cardiology: Radiation Dosimetry, Uncertainties, and Risk
- Uncertainties in Internal Dose Calculations for Radiopharmaceuticals
- High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
- Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer
- Toward Patient-Friendly Cell-Level Dosimetry
- 186Re-HEDP in the Treatment of Patients with Inoperable Osteosarcoma
- Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-D-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review